Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02325414
Other study ID # STU00098239
Secondary ID A-18350
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2015
Est. completion date August 25, 2020

Study information

Verified date June 2021
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.


Description:

This is a randomized, double-blind placebo-controlled study of zoledronic acid to evaluate its efficacy and safety over a 2 year period for the prevention of bone loss and maintenance of bone strength in individuals with recent onset SCI (see diagram below). Subjects will be randomized at the baseline visit to receive either zoledronic acid or placebo. At the end of the first year of the study, each treatment group will be re-randomized to either zoledronic acid or placebo to evaluate the durability of response to zoledronic acid and the utility of serum bone markers to guide therapeutic decision making. DXA imaging, CT imaging and bone markers will be obtained at baseline, 3 months, 6 months, 12 months, 18 months and 24 months.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 25, 2020
Est. primary completion date August 25, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - In-patient at Rehabilitation Institute of Chicago (RIC) or an outpatient who was recently discharged from RIC - Males and females - Age >/=18 years - Medically stable in the opinion of subject's physiatrist - SCI at within 120 days inclusive at time of screening - SCI with inability to ambulate independently - ASIA Impairment Scale (AIS) A, B, or C, at time of study entry - Capable of positioning to have DXA performed - Able to tolerate acetaminophen - No known endocrinopathies (diabetes type 1 or 2 can be included) - Normal TSH levels - Normal 25-OH vitamin D levels (>/= 20 ng/ml) at baseline (subjects may be repleted) - Normal calcium levels - Normal renal function (creatinine <2.0 mg/dl) - Well hydrated with adequate intake of liquids - Able to return for all follow-up visits - Capable of reading and understanding informed consent document - Males and females of childbearing potential must be willing and able to use double barrier method of contraception for 2 months after having received study drug Exclusion Criteria: - Have Paget's disease of the bone - Malignancy as a cause of acute SCI - Have unexplained high levels of alkaline phosphatase in blood - Any active gastrointestinal condition that results in malabsorption - Poor dental hygiene or requirement for invasive dental procedure within two months prior to enrollment - History of bone metastasis and skeletal malignancies - History of alcoholism or drug abuse within the 2 years prior to study screening - Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study - Elevated liver function tests >2x normal - Currently being prescribed anti-convulsants at a dose or frequency that is determined to interfere with bone metabolism as determined by the investigator - Currently being prescribed glucocorticoids, other than inhaled glucocorticoids - Current or recent use any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds within 60 days of screening. - Pregnant, planning to become pregnant, or lactating

Study Design


Intervention

Drug:
Zoledronic acid
Intravenous infusion of zoledronic acid 5 mg.
Placebo
Placebo (saline) infusion to match zoledronic acid

Locations

Country Name City State
United States Northwestern University Feinberg School of Medicine Chicago Illinois
United States Rehabilitation Institute of Chicago Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change in Bone Mass Density (BMD) in the Hip Percent change of bone mass density (BMD) in the total hip (as measured by DXA) 0-12 months
Primary Percent Change of Bone Mass Density (BMD) in the Femoral Neck Percent change of bone mass density (BMD) in the femoral neck (as measured by DXA) 0-12 months
Secondary Percent Change in the Epiphyseal Integral Bone Mass Content (iBMC) of the Femur Percent change in the epiphyseal integral bone mass content (iBMC) of the femur, as collected by CT. 0-12 months
Secondary Percent Change in the Metaphyseal Integral Bone Mass Content (iBMC) of the Femur Percent change in the metaphyseal integral bone mass content (iBMC) of the femur, as collected by CT 0-12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Completed NCT02143674 - Muscle Strengthening Exercises and Global Stretching in Elderly N/A
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A